Join us in Boston on March 27, where our Co-founder and CEO, Hong I. Wan will be speaking at the Novel Conjugates Summit. Hong will be discussing:? ? The scientific rationale behind TAC-001 – a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22? ? Insights from the ongoing TAC-001 Phase 1/2 clinical trial for advanced or metastatic solid tumors? ? A novel Nectin-4 ADC with differentiated preclinical safety and efficacy dataset ? The potential of Tallac’s next-gen ADC platform for systemically administered immune agonist conjugates. Find out more about our session: https://lnkd.in/dkgAuxKh #NovelConjugatesSummit #Oncology #CancerTherapeutics #TRAAC #ConjugatedTherapies
Tallac Therapeutics
生物技术研究
Next generation immunotherapies for cancer patients: harnessing the power of innate and adaptive immune systems
关于我们
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.
- 网站
-
https://www.tallactherapeutics.com
Tallac Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Burlingame
- 类型
- 私人持股
地点
-
主要
获取路线
866 Malcom Rd
Suite 100
US，Burlingame
Tallac Therapeutics员工
动态
-
Hong I. Wan, our Co-founder and CEO, will be attending the IO 360° Summit (March 24-26), where industry experts will share the latest insights in immuno-oncology, including biomarkers, antibody-drug conjugates (ADCs), cell therapy, and more. Will you be there? Let’s connect. #IO360 #IO360Summit #ImmunoOncology #ADC #Biotech
-
-
We recently convened leading gastrointestinal cancer experts in San Francisco for Tallac's Biliary Tract Cancer Advisory Board Meeting, held on the eve of the 2025 American Society of Clinical Oncology (ASCO) GI Cancers Symposium. Together, we explored the potential of TAC-001 to address unmet medical needs in biliary tract cancers. We are grateful for the invaluable insights shared by our esteemed advisors, which will help shape the future of cancer treatment. #Oncology #Innovation #Collaboration #CancerResearch?#CancerCare #GastrointestinalCancer #ASCOGI
-
-
-
-
-
+2
-
-
Last week, we gathered for our annual holiday luncheon to celebrate an incredible year and the talented team that made it happen at Tallac Therapeutics. Wishing everyone a joyous holiday season and looking forward to another year of success, growth, and teamwork with our amazing team!
-
-
-
-
-
+2
-
-
Last month at The Society for Immunotherapy of Cancer Annual Meeting #SITC2024, we had the opportunity to connect with pioneering scientists, clinicians, and drug developers who are collaboratively working towards bringing better medicine to cancer patients.
@SITC2024 with Laura qm C., Tallac CMO. Great to see the fascinating science and promising clinical results! These few days spent with pioneering scientists, clinicians and drug developers all working together to bring better medicine to cancer patients fill me with energy and inspiration!
-
-
Tallac Therapeutics and Clarivate join for?Technology Networks panel discussion We are pleased to announce that Hong I. Wan, our President, CEO, and Co-founder, will be speaking at the upcoming Technology Networks online symposium, Advances in Drug Discovery & Development 2024. Hong will be joined by Matthew Arnold and Mike Ward from Clarivate to talk about the current ADC landscape and innovations to watch for. Watch the live panel discussion tomorrow, September 19th, 8-9 am PDT (11 am -12 pm EDT). Find out more about the session and register to attend the symposium:?https://lnkd.in/eKMKKHWM #DrugDiscovery #DrugDevelopment #ADC
-
-
Celebrating Tallac's 4th?Anniversary ?? Our Tallac Therapeutics team recently celebrated the company's fourth anniversary at Pinstripes in San Mateo. It was a night filled with bowling, delicious food, and great company. As we enter our 5th year, we reflect on past achievements, including the advancement of our lead immunostimulatory ADC program and the presentation of preliminary clinical data for TAC-001 at key industry conferences, such as SITC and AACR. None of this would have been possible without our dedicated team. Tallac Therapeutics is grateful for your hard work and commitment. Here's to many more years of success, innovation, and celebration! Check out the team photo from the team event below. Hong I. Wan, Curtis Hecht, Pavel Strop, Janet Sim 沈彬, Bora Han, Laura qm Chow #TallacTherapeutics #HarnessingThePower #CancerResearch #Oncology #ADCs
-
-
Did you see our feature in this BioSpace article? In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability. Read the full article here: https://lnkd.in/gi779jJu https://lnkd.in/gkWcfTXt
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy. https://hubs.li/Q02FyS5B0
-
Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs). https://lnkd.in/gpCVzZGy
Clarivate released the 2024 Companies to Watch report, highlighting seven innovative companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. The companies - Adcendo, Araris Biotech AG, GO Therapeutics, Heidelberg Pharma AG, Pheon Therapeutics, Tallac Therapeutics, Tubulis GmbH – are transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest. The report, based on data from BioWorld News and an analysis of drug benefits, financing, and R&D activity, explains why these companies are significant innovators. "Data reveals a clear trend: Big Pharma is swiftly integrating ADCs into their portfolios through partnerships and acquisitions. ADCs are rapidly maturing in the clinical space, expanding beyond oncology into diverse therapeutic areas” quotes Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate. Read more: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma
-
-
We're excited to share that?Hong I. Wan, our President, CEO, and Co-founder, will be speaking at the STING & TLR-Targeted Therapies Summit, hosted by Hanson Wade, on June 19th in San Diego, CA. Hong will present the scientific rationale behind TAC-001, outlining the ongoing TAC-001 phase ? clinical trial for advanced or metastatic solid tumors and delving into the potential of?Tallac Therapeutics' novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates. Find out more:?https://lnkd.in/gcZiDPn3 #STING #TLRtargetedtherapies #cancerresearch #immunotherapy #immunooncology
-